Disc Medicine FDA Rejection, Lawsuit
Analysis based on 7 articles · First reported May 01, 2026 · Last updated May 12, 2026
The market is impacted by the potential for a class action lawsuit against Disc Medicine, Inc., which could lead to financial penalties and further stock price depreciation. Investors in Disc Medicine, Inc. are facing losses due to the United States — Food and Drug Administration's decision.
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. following a significant drop in its stock price. This decline occurred on February 13, 2026, after the United States — Food and Drug Administration issued a Complete Response Letter for Disc Medicine, Inc.'s bitopertin program, indicating that the new drug application could not be approved due to uncertainties requiring additional evidence. Rosen Law Firm is preparing a class action lawsuit to recover investor losses, alleging that Disc Medicine, Inc. may have issued materially misleading business information to the investing public. Philip Kim and Lawrence Rosen are key contacts for investors interested in joining the prospective class action.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard